Drug intelligence / Profile preview

IMPAKT-197

Development stage: Preclinical
Lead developer: Immvue Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

IMPAKT-197 is a small molecule inhibitor of Interleukin-2-inducible T-cell kinase (ITK) being developed by Immvue Therapeutics. ITK is a member of the Tec family of non-receptor tyrosine kinases and plays a critical role in T-cell signaling and activation. By targeting ITK, IMPAKT-197 aims to modulate the immune response within the tumor microenvironment, potentially enhancing anti-tumor immunity. The drug is currently in the IND-enabling phase for the treatment of solid tumors.

Targets

ITK (Interleukin 2-inducible T-cell kinase)

Beyond the preview

Go deeper on IMPAKT-197.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMPAKT-197.

Explore the full profile